Protocol Ledger

NCT04604184 · Phase II · TERMINATED

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

Interventional Phase II clinical trial protocol NCT04604184 sponsored by Boehringer Ingelheim in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-03 Enrollment: 133 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04604184
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)133 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04604184
Protocol FieldVerified Registry Value
NCT IdentifierNCT04604184
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment133 participants (ACTUAL)
Registered Start Date2020-11-03
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04604184
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI